Maltofer^®

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro idiopatické střevní záněty ISCARE I. V. F. a. s. a Ústav lékařské biochemie a laboratorní diagnostiky, 1. LF UK a VFN v Praze
Published in: Gastroent Hepatol 2015; 69(2): 180-182
Category: Drug Profile
doi: https://doi.org/10.14735/amgh2015180

Sources

1. Státní ústav pro kontrolu léčiv. SPC přípravku Maltofer tablety SUKL 9.5.2012 (č.j. 41555/ 2012). [online]. Dostupné z: http:/ / www.sukl.cz/ .

2. Dietzfelbinger H. Bioavailability of bi‑ and trivalent oral iron preparations. Investigations of iron absorption by postabsorption serum iron concentrations curves. Arzneimittelforschung 1987; 37(1A): 107– 112.

3. Nielsen P, Gabbe EE, Fischer R et al. Bioavailability of iron from oral ferric polymaltose in humans. Arzneimittelforschung 1994; 44(6): 743– 748.

4. Jacobs P, Wormald L. The bioavailability of an iron polymaltose complex for treatment of iron deficiency. J Med 1979; 10(4): 279– 285.

5. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3(1): 12– 33. doi: 10.3390/ pharmaceutics3010012.

6. Geisser P. Safety and efficacy of iron(III)- hydroxide polymaltose complex – a review of over 25 years experience. Arzneimittelforschung 2007; 57(6A): 439– 452.

7. Jacobs P, Johnson G, Wood L. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. J Med 1984; 15(5– 6): 367– 377.

8. Kaltwasser JP, Werner E. Assessment of bioavailability of oral iron preparations in man. In: Forth W (ed). Iron. Bioavailability, absorption, utilization 1993: 31– 57.

9. Kaltwasser JP, Werner E, Niechzial M. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneimittelforschung 1987; 37(1A): 122– 129.

10. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol 2007; 69: 69– 85.

11. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102(3): 783– 788.

12. EMEA guideline. CPMP/ EWP/ QWP/ 1401/ 98 London 2001.